Since its 2020 IPO, Harmony Biosciences has delivered a compound annual growth rate of approximately 40% in net product sales of its narcolepsy treatment Wakix, taking annual revenues from roughly $120 million in 2020 to nearly $870 million by year-end 2023. The drug’s gross margin of about 75% has helped Harmony turn profitable, generating $186 million in net income in 2023. This level of profitability is rare among young biotech firms and has provided Harmony with the capital flexibility to invest in R&D without resorting to dilutive equity offerings.

Wakix, approved by the FDA in August 2019 as the only non–controlled-substance option for narcolepsy, has enrolled about 8,000 of the estimated 170,000 U.S. patients diagnosed or undiagnosed with the condition. New patient starts have averaged several hundred per quarter over the past year, positioning Wakix as one of the most successful rare-disease launches. Harmony’s patient-access initiatives, including co-pay assistance and telehealth partnerships, have contributed to a sequential quarter-over-quarter increase in new prescriptions of 20% in Q4 2023 compared with Q3.

Despite robust financial performance, Harmony’s share price has remained flat since its IPO, reflecting investor concern over intensifying competition and legal timing. Jazz Pharmaceuticals’ established narcolepsy treatments—Xywav and Xyrem—control the majority of the market and could limit Wakix’s long-term pricing power. Additionally, Wakix’s composition-of-matter patent expires in 2030, leaving just seven years of exclusivity. A 2023 short-seller report alleging undisclosed safety issues, though never substantiated, also introduced reputational risk that continues to shadow the stock.

Harmony’s balance sheet, strengthened by Wakix cash flows, underpins an expanding pipeline targeting rare neurologic disorders beyond narcolepsy. The company has three mid-stage clinical programs addressing conditions with combined prevalence of 50,000 to 100,000 patients in the U.S. Harmony plans to allocate approximately 30% of annual R&D spend—projected at $75 million in 2024—to these programs, aiming for at least one additional FDA submission by 2026. Successful diversification could extend the company’s revenue runway beyond the 2030 patent cliff and drive a re-rating of its valuation.